FrancophonIA/ELRC3.0 huggingface dataset:
English: This should be taken into account if NexoBrid is used in patients receiving CYP2C8 substrates (including amiodarone, amodiaquine, chloroquine, fluvastatin, paclitaxel, pioglitazone, repaglinide, rosiglitazone, sorafenib and torasemide) and CYP2C9 substrates (including ibuprofen, tolbutamide, glipizide, losartan, celecoxib, warfarin, and phenytoin).
Slovenian: To je treba upoštevati, če se zdravilo NexoBrid uporablja pri bolnikih, ki prejemajo substrate CYP2C8 (vključno z amiodaronom, amodiakinom, klorokvinom, fluvastatinom, paklitakselom, pioglitazonom, repaglinidom, rosiglitazonom, sorafenibom in torazemidom) in substrati CYP2C9 (vključno z ibuprofenom, tolbutamidom, glipizidom, losartanom, celekoksibom, varfarinom in fenitoinom).
English: • The removal of NexoBrid and of dissolved eschar
Slovenian: • Odstranitev zdravila NexoBrid in odpuščenih eshar
English: ITT (Intent To Treat population): all randomized patients The difference in time to complete wound closure is mainly related to the wound care strategy applied by the physician, where an attempt to minimise grafting and allow for spontaneous epithelialisation of the wound areas that still have dermis may prolong time to first autograft (time to autograft: NexoBrid: 14.7 days vs. SOC: 5.9 days) and hence prolong complete wound closure.
Slovenian: ITT (populacija z namenom zdravljenja (Intent To Treat population)): vsi randomizirani bolniki Razlika v času do popolnega zaprtja rane je v glavnem povezana s strategijo nege rane, ki jo uporabi zdravnik, pri čemer lahko poskus zmanjšanja presaditev in omogočenja spontane epitelializacije predela rane s kožo podaljša čas do prvega avtotransplantata (čas do avtotransplantata: zdravilo NexoBrid: 14,7 dni v primerjavi s standardno nego: 5,9 dni) in s tem podaljša popolno zaprtje rane.
English: Due to safety considerations (see also section 4.4, Coagulopathy) NexoBrid should not be applied to more than 15%Total Body Surface Area (TBSA).
Slovenian: Zaradi varnostnih pomislekov (glejte tudi poglavje 4.4, Koagulopatija) zdravila NexoBrid ne nanašajte na več kot 15 % celotne površine telesa (CPT).
English: Days (mean ± SD) (Number of wounds)
Slovenian: Število dni (povprečje ± SD) (število ran)
English: The use of NexoBrid in subsequent burn injury is not recommended.
Slovenian: Kasnejše uporabe zdravila NexoBrid za nadaljnje opeklinske rane se ne priporoča.
English: The use of NexoBrid to remove burnt tissue may lead to fever, to wound inflammation or wound infection, and possibly to general infection.
Slovenian: Uporaba zdravila NexoBrid za odstranjevanje opečenega tkiva lahko povzroči povišano telesno temperaturo, vnetje rane ali okužbo rane, morda pa tudi splošno okužbo.
English: Animal studies are insufficient to properly assess the potential of NexoBrid to interfere with embryonal/foetal development (see section 5.3).
Slovenian: Ni dovolj študij na živalih za pravilno oceno možnosti vpliva zdravila NexoBrid na razvoj zarodka ali plodu (glejte poglavje 5.3).
English: 60% of the treated wounds area was partial thickness and/or full thickness.
Slovenian: 60 % zdravljenih predelov so bile dermalne in/ali subdermalne opeklinske rane.
English: Other medicines and NexoBrid Tell your doctor if you are taking, have recently taken or might take any other medicines.
Slovenian: Obvestite svojega zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero katero koli drugo zdravilo.
English: Topically applied antibacterial medicinal products (e.g. silver sulfadiazine or povidone iodine) may decrease the efficacy of NexoBrid (see section 4.4).
Slovenian: Topikalno nanesena protibakterijska zdravila (kot sta srebrov sulfadiazin ali povidon-jod) lahko zmanjšajo učinkovitost zdravila NexoBrid (glejte poglavje 4.4).
English: Store and transport refrigerated (2C-8C).
Slovenian: Zdravilo shranjujte in prevažajte v hladnem (2 C - 8 C).
English: • The vial containing NexoBrid powder, gel bottle, and the prepared NexoBrid gel should only be used for one patient.
Slovenian: • Vialo, ki vsebuje zdravilo NexoBrid prašek, stekleničko z gelom in pripravljeno zdravilo NexoBrid gel, lahko zdravnik uporabi samo za enega bolnika.
English: • After 4 hours of NexoBrid treatment, the occlusive dressing must be removed using aseptic techniques.
Slovenian: • Po 4 urah zdravljenja z zdravilom NexoBrid morate okluzivno oblogo odstraniti z aseptično tehniko.
English: Cmax was 6020 ± 5020 ng/ml (mean ± SD) for the group of 15 patients, with a range of 888 to 15,700 ng/ml.
Slovenian: Cmax je bil 6.020 ± 5.020 ng/ml (povprečje ± SD) za skupino 15 bolnikov, z razponom 888 do 15.700 ng/ml.
English: Common side effects (may affect up to 1 in 10 people) - Pain (even if medicines are used to prevent or lessen pain caused by the removal of burnt tissue) - Infection of the burn wound - Complications of the wound including; wound opening, wounds drying out and breaking down and failure of skin grafts to heal properly
Slovenian: Pogosti neželeni učinki (prizadenejo lahko največ 1 od 10 bolnikov) - bolečina (tudi ob uporabi zdravil za preprečevanje ali blaženje bolečine, ki jo povzroči odstranjevanje opečenega tkiva) - okužba opeklinske rane - zapleti z rano, vključno z odprtjem rane, izsušitvijo rane in raztrganjem ali neustreznim celjenjem kožnih presadkov
English: There is limited pharmacokinetic data in patients with TBSA of more than 15%.
Slovenian: Pri bolnikih z opeklinami na več kot 15 % CPT so farmakokinetični podatki omejeni.
English: • The gel should be prepared at the patient's bedside.
Slovenian: • Gel morate pripraviti ob bolnikovi postelji.
English: To prevent wound-healing problems, the treated burn wound will be covered as soon as possible by temporary or permanent skin substitutes or dressings.
Slovenian: Da preprečite težave s celjenjem rane, bo obdelana opeklinska rana takoj, ko je mogoče, prekrita z začasnim ali stalnim kožnim nadomestkom ali oblogo.
English: The AUC from time zero to 48 hours after administration (AUClast) was 43,400 ± 46,100 ngh/ml (mean ± SD) for the group of 15 patients, with a range of 4560-167,000 ngh/ml.
Slovenian: AUC od časa nič do 48 ur po uporabi (AUClast) je bil 43.400 ± 46.100 ngh/ml (povprečje ± SD) za skupino 16 bolnikov, z razponom 4.560-167.000 ngh/ml.
English: Each NexoBrid vial, gel, or reconstituted gel should be used for a single patient only.
Slovenian: Vsako vialo zdravila NexoBrid gel ali rekonstituiranega gela uporabite samo za enega bolnika.
English: • When opening the gel bottle, it must be confirmed that the tamper-evident ring is separating from the bottle's cap.
Slovenian: • Pri odpiranju stekleničke z gelom morate preveriti, da se je varnostni obroček ločil od zaporke steklenice.
English: Rubbing will not remove adhering undissolved eschar in areas where the eschar still remains.
Slovenian: Z drgnjenjem ne boste odstranili neodluščenih eshar na predelih, kjer so ostale.
English: • The NexoBrid powder and gel are sterile.
Slovenian: • Zdravilo NexoBrid prašek in gel sta sterilna.
English: If the tamper-evident ring was already separated from the cap before opening, the gel bottle must be discarded and another, new gel bottle used.
Slovenian: Če je bil varnostni obroček že odtrgan od zaporke, preden ste jo odprli, morate steklenico z gelom zavreči in uporabite drugo, novo steklenico z gelom.
English: Cross-sensitivity
Slovenian: Križna senzibilizacija
English: Benefit/risk assessment should include consideration of the greater frequency of concomitant disease or other medicinal product therapy in the elderly.
Slovenian: Pri oceni razmerja med koristmi in tveganjem je treba upoštevati, da je pri starejših bolnikih pogostnost sočasnih obolenj ali sočasnega zdravljenja z drugimi zdravili večja.
English: NexoBrid may reduce the ability of your blood to form clots, which increases the risk of bleeding.
Slovenian: Zdravilo NexoBrid lahko zmanjša sposobnost strjevanja krvi in s tem poveča tveganje za krvavitev.
English: NexoBrid should be used with caution if you have a general tendency to bleed, a stomach ulcer, blood poisoning, or another condition that could cause you to bleed.
Slovenian: Zdravilo NexoBrid je treba uporabljati previdno, če ste na splošno nagnjeni h krvavitvam, razjedi želodca, zastrupitvi krvi ali drugim stanjem, ki lahko povzročijo krvavitev.
English: It is unknown whether concentrate of proteolytic enzymes enriched in bromelain or its metabolites are excreted in human milk.
Slovenian: Ni znano, ali se koncentrat proteolitičnih encimov, obogaten z bromelainom, ali njegovi presnovki izločajo v materino mleko.
English: NexoBrid may: - increase the effects of certain medicines that are inactivated by a liver enzyme called CYP2C8 and CYP2C9.
Slovenian: Zdravilo NexoBrid lahko: - poveča učinke nekaterih zdravil, ki jih jetrna encima, imenovana CYP2C8 in CYP2C9, deaktivirata.
English: Since the safe use of NexoBrid during pregnancy has not yet been established, NexoBrid is not recommended during pregnancy.
Slovenian: Ker varnosti uporabe zdravila NexoBrid med nosečnostjo še niso dokazali, zdravila NexoBrid ne uporabljajte pri nosečnicah.
English: No interaction studies with NexoBrid have been performed.
Slovenian: Študij medsebojnega delovanja z zdravilom NexoBrid niso izvedli.
English: In NexoBrid studies wounds with visible dermal remnants were allowed to heal by spontaneous epithelialisation.
Slovenian: V študijah z zdravilom NexoBrid so pustili, da so se rane z vidnimi ostanki kože zacelile s spontano epitelializacijo.
English: The gel is clear and colourless.
Slovenian: Gel je prozoren in brezbarven.
English: • The debrided area must be covered immediately by temporary or permanent skin substitutes or dressings to prevent desiccation and/or formation of pseudoeschar and/or infection.
Slovenian: • Očiščen predel morate takoj prekriti z začasnim kožnim nadomestkom ali stalnim kožnim presadkom ali oblogo, da se ne osuši in/ali ne nastanejo psevdoeshare in/ali okužbe.
English: In studies without antibacterial soaking, pyrexia or hyperthermia was reported in 35.6% of NexoBridtreated patients compared with 18.6% in control patients.
Slovenian: V študijah brez antibakterijskega namakanja so o pireksiji ali hipertermiji poročali pri 35,6 % bolnikov, zdravljenih z zdravilom NexoBrid, v primerjavi z 18,6 % bolnikov iz kontrolne skupine.
English: The efficacy of NexoBrid in humans was evaluated, compared to standard of care, in a randomised, multi-centre, multi-national, open-label, confirmatory phase 3 study in hospitalised patients with deep partial- and/or full-thickness thermal burns of 5 to 30% Total Body Surface Area (TBSA), but with total burn wounds of no more than 30% TBSA.
Slovenian: Učinkovitost zdravila NexoBrid pri ljudeh je bila ocenjena glede na standardno nego v randomizirani, multicentričini, multinacionalni, odprti, potrditveni študiji 3. faze pri hospitaliziranih bolnikih z globokimi dermalnimi in subdermalnimi opeklinami 5 do 30 % celotne površine telesa (CPT) in s skupnimi opeklinskimi ranami do 30 % CPT.
English: Non-autografted wounds (ITT)
Slovenian: Rane brez avtotransplantata (ITT)
English: In phase 2 and phase 3 clinical studies, certain types of wound complications were reported more frequently in the NexoBrid group than in the group treated according to the study sites' Standard of Care (SOC).
Slovenian: V kliničnih študijah 2. in 3. faze so o nekaterih vrstah zapletov z rano poročali pogosteje v skupini z zdravilom NexoBrid, kot pri skupini, zdravljeni v skladu s standardno terapijo.
English: • The area from which you wish to remove the eschar must be surrounded with a sterile paraffin ointment adhesive barrier by applying it a few centimetres outside of the treatment area (using a dispenser).
Slovenian: • Površino, s katere želite odstraniti esharje, morate obdati z adhezivno pregrado iz sterilnega parafinskega mazila, ki ga nanesete nekaj centimetrov zunaj zdravljenega predela (uporabite razdeljevalec).
English: There is only limited safety data from the use in the paediatric population.
Slovenian: Podatkov o varnosti pri pediatrični populaciji je malo.
English: Direct contact with the eyes should be avoided.
Slovenian: Preprečite neposredni stik z očmi.
English: Before use, the powder must be mixed with the gel producing a uniform gel.
Slovenian: Pred uporabo je treba prašek zmešati z gelom, da nastane enakomeren gel.
English: It is not known if NexoBrid application has any clinically relevant effect on haemostasis.
Slovenian: Ni znano, ali ima nanos zdravila NexoBrid klinično pomemben učinek na hemostazo.
English: NexoBrid should only be applied by trained healthcare professionals in specialist burn centres.
Slovenian: Zdravljenje z zdravilom NexoBrid lahko izvaja le usposobljeni zdravstveni delavec v specializiranem centru za opekline.
English: • Summary of Product Characteristics and Patient Information Leaflet
Slovenian: • Povzetek glavnih značilnosti zdravila in navodilo za uporabo
English: If too much NexoBrid is used If too much NexoBrid gel is applied on a burn wound, excess gel may be wiped off.
Slovenian: Če je bil uporabljen preveliki odmerek zdravila NexoBrid Če se na rano nanese preveč zdravila NexoBrid gel, se presežek gela obriše.
English: NexoBrid contains a mixture of enzymes called “concentrate of proteolytic enzymes enriched in bromelain”, which is produced from an extract from the stem of the pineapple plant.
Slovenian: Zdravilo NexoBrid vsebuje mešanico encimov, imenovano "koncentrat proteolitičnih encimov, obogatenih z bromelainom", ki se izdelujejo iz ekstrakta iz stebla rastline ananasa.
English: The use of NexoBrid during pregnancy is not recommended.
Slovenian: Uporaba zdravila NexoBrid med nosečnostjo ni priporočljiva.
English: The efficacy of eschar removal was evaluated by determining the percentage of wound area left with eschar that required further removal by excision or dermabrasion, and the percentage of wounds requiring such surgical removal.
Slovenian: Učinkovitost odstranitve eshar so ocenili z ugotavljanjem odstotka predela rane, na katerem so eshare ostale, in kjer jih je bilo treba naknadno odstraniti z ekscizijo ali dermabrazijo, in odstotkom ran, pri katerih je bila potrebna kirurška odstranitev.
English: The available data are limited and NexoBrid should not be used in patients younger than 18 years.
Slovenian: Razpoložljivih podatkov je malo, zato se zdravila NexoBrid ne sme uporabljati pri bolnikih, mlajših kot 18 let.
English: See also section 4.4.
Slovenian: Glejte poglavje 4.4.
English: • The method of preparation of NexoBrid and of its application to wound area
Slovenian: • Način priprave zdravila NexoBrid in aplikacije na predel rane
English: NexoBrid should be used within 15 minutes after mixing the powder with the gel.
Slovenian: Zdravilo NexoBrid uporabite v 15 minutah po mešanju praška z gelom.
English: The treated area must be rubbed until the appearance of a pinkish surface with bleeding points or a whitish tissue.
Slovenian: Zdravljeni predel morate drgniti, dokler ne opazite rožnato površino s krvavimi pikicami ali belkasto tkivo.
English: • The wound must be cleaned thoroughly and the superficial keratin layer or blisters removed from the wound area, as the keratin will isolate the eschar from direct contact with NexoBrid and prevent eschar removal by NexoBrid.
Slovenian: • Rano morate temeljito očistiti in odstraniti odvečne plasti keratina ali mehurje s predela rane, saj bo keratin preprečil neposreden stik eshar z zdravilom NexoBrid in preprečil, da bi zdravilo NexoBrid eshare odstranilo.
English: Treatment with concentrate of proteolytic enzymes enriched in bromelain prepared in a powder:gel ratio of 1:5 (0.16g per g of mixed gel) in patients with deep partial- and/or full-thickness burns within the framework of a clinical study did not result in significantly different safety findings when compared to treatment with concentrate of proteolytic enzymes enriched in bromelain prepared in a powder:gel ratio of 1:10 (0.09 g per 1g of mixed gel).
Slovenian: Zdravljenje s koncentratom proteolitičnih encimov, obogatenih z bromelainom, pripravljenim v razmerju prašek:gel 1:5 (0,16 g na g mešanega gela) pri bolnikih z globokimi dermalnimi in subdermalnimi opeklinami v okviru klinične študije ni imelo za posledico značilno drugačnih izsledkov o varnosti, ko so jih primerjali z zdravljenjem s koncentratom proteolitičnih encimov, obogatenih z bromelainom, pripravljenimi v razmerju prašek:gel 1:10 (0,09 g na 1 g mešanega gela).
English: A single intravenous infusion of a solution prepared from NexoBrid powder in the mini-pig was well tolerated at dose levels of up to 12 mg/kg (achieving plasma levels 2.5fold of the human plasma level after application of the clinical proposed dosage to 15% TBSA) but higher doses were overtly toxic, causing haemorrhage in several tissues.
Slovenian: Enojno intravensko infuzijo raztopine, pripravljene iz zdravila NexoBrid prašek, so mini-prašički dobro prenašali pri ravneh odmerkov do 12 mg/kg (dosežene ravni v plazmi so bile 2,5-kratne od ravni v plazmi pri ljudeh po nanosu klinično predlaganega odmerka na 15 % CPT), medtem ko so bili višji odmerki zelo toksični in so v številnih tkivih povzročili krvavitve.
English: What NexoBrid looks like and contents of the pack
Slovenian: Izgled zdravila NexoBrid in vsebina pakiranja
English: No dose adjustment is required.
Slovenian: Odmerka ni treba prilagajati.
English: The NexoBrid gel must fill the entire occlusive dressing, and special care should be taken not to leave air under this occlusive dressing.
Slovenian: Zdravilo NexoBrid gel mora zapolniti celotno okluzivno oblogo, pri čemer je potrebna posebna pozornost, da pod okluzivno oblogo ne pride zrak.
English: • The adhesive barrier must be removed using a sterile blunt-edged instrument (e.g., tongue depressor).
Slovenian: • Adhezivno pregrado morate odstraniti s sterilnim topim inštrumentom (npr. paličico za jezik).
English: Using NexoBrid may reduce the need for, or the extent of, surgical removal of burnt tissue and/or skin transplantation.
Slovenian: Z uporabo zdravila zdravila NexoBrid se lahko zmanjšata potreba in obseg kirurške odstranitve opeklega tkiva in/ali presaditve.
English: The frequencies of the adverse reactions presented below reflect the use of NexoBrid to remove eschar from deep partial- or full-thickness burns in a regimen with local antibacterial prophylaxis, recommended analgesia, as well as coverage of the wound area after application of NexoBrid for 4 hours with an occlusive dressing for containment of NexoBrid on the wound.
Slovenian: Spodaj predstavljene pogostnosti neželenih učinkov izhajajo iz uporabe zdravila NexoBrid za odstranjevanje eshar z globokih dermalnih in subdermalnih opeklin pri režimu z lokalno antibakterijsko profilakso, priporočeno analgezijo ter prekrivanjem predela rane po nanosu zdravila NexoBrid za 4 ure z okluzivno oblogo, ki zadrži zdravilo NexoBrid na rani.
English: A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Slovenian: A. IZDELOVALCI BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
English: Prevention of wound complications
Slovenian: Preprečevanje zapletov z rano
English: If you notice any of these signs or symptoms, inform your doctor or caregiver immediately.
Slovenian: Če opazite katere koli od teh znakov ali simptomov, takoj obvestite svojega zdravnika ali negovalca.
English: NexoBrid is used in adult patients to remove burnt tissue from deep or partially deep burn wounds of the skin.
Slovenian: Zdravilo NexoBrid se uporablja pri odraslih bolnikih za odstranjevanje opečenega tkiva iz subdermalnih ali dermalnih opeklinskih ran kože.
English: Blood pressure should be monitored in patients receiving ACE inhibitors
Slovenian: Pri bolnikih, ki prejemajo zaviralce ACE, je treba spremljati krvni tlak.
English: If you notice any of these symptoms or signs, inform your doctor or caregiver immediately.
Slovenian: Če opazite katere koli od teh simptomov ali znakov, takoj obvestite svojega zdravnika ali negovalca.
English: Warnings and precautions Talk to your doctor or nurse before NexoBrid is used if
Slovenian: Opozorila in previdnostni ukrepi Pred uporabo zdravila NexoBrid se pogovorite s svojim zdravnikom ali medicinsko sestro,
English: If NexoBrid goes into the eyes, wash them with lots of water for at least 15 minutes.
Slovenian: Če zdravilo NexoBrid pride v oči, jih vsaj 15 minut izpirajte z veliko vode.
English: The mixture of enzymes in NexoBrid dissolves burn wound eschar.
Slovenian: Mešanica encimov v zdravilu NexoBrid raztopi eshar z opeklinske rane.
English: NexoBrid is not indicated for use in patients younger than 18 years.
Slovenian: Zdravilo NexoBrid ni indicirano za uporabo pri bolnikih, mlajših od 18 let.
English: MediWound Germany GmbH 65428 Rüsselsheim Germany
Slovenian: MediWound Germany GmbH 65428 Rüsselsheim Nemčija
English: Concentrate of proteolytic enzymes enriched in bromelain is a debriding agent, applied topically for removal of eschar in deep partial- and full-thickness burns.
Slovenian: Koncentrat proteolitičnih encimov, obogatenih z bromelainom, je čistilna snov, ki se topikalno nanaša za odstranitev eshar pri globokih dermalnih in subdermalnih opeklinah.
English: • NexoBrid gel should be prepared at the patient's bedside.
Slovenian: • Gel zdravila NexoBrid morate priprabiti ob bolnikovi postelji.
English: Careful consideration should also be given to placing permanent skin covers (e.g. autografts) on deep partial thickness wounds soon after NexoBrid debridement.
Slovenian: Razmisliti je treba tudi o namestitvi trajnih kožnih prekritij (npr. avtotransplantatov) na globoke dermalne rane kmalu po očiščenju z zdravilom NexoBrid.
English: As a precautionary measure, you should not breast-feed for at least 4 days after NexoBrid application.
Slovenian: Kot previdnostni ukrep vsaj 4 dni po nanosu zdravila NexoBrid ne smete dojiti.
English: • The dissolved eschar must be removed from the wound by wiping it away with a sterile bluntedged instrument.
Slovenian: • Odluščene eshare morate odstraniti z rane tako, da jih obrišete s sterilnim topim inštrumentom.
English: The age range in the SOC group was 5.1 to 55.7 years.
Slovenian: Razpon starosti v skupini, zdravljeni s standardno nego, je bil 5,1 do 55,7 let.
English: NexoBrid should be left in contact with the burn for a duration of 4 hours.
Slovenian: Zdravilo NexoBrid naj bo 4 ure v stiku z opeklino.
English: NexoBrid was applied once to the burn wound at a dose of 2 g NexoBrid Powder/20 g gel/100 cm of skin.
Slovenian: Zdravilo NexoBrid so na opeklinsko rano nanesli enkrat v odmerku 2 g zdravila NexoBrid prašek/20 g gela/100 cm kože.
English: When applying a permanent skin cover (e.g., autograft) or temporary skin substitute (e.g., allograft) to a freshly enzymatically debrided area, care should be taken to clean and refresh the debrided bed by, e.g., brushing or scraping to allow dressing adherence.
Slovenian: Pri nanosu stalnega kožnega presadka (npr. avtotransplantata) ali začasnega kožnega nadomestka (npr. alotransplantata) na svež encimsko očiščen predel, bodite pozorni na čiščenje in osvežitev očiščene rane, npr. s ščetkanjem ali strganjem, da se obloga sprime.
English: SN: {number}
Slovenian: < PC: {številka} SN: {številka} NN: {številka}>
English: The range of total dose applied was 5 to 30 g concentrate of proteolytic enzymes enriched in bromelain from NexoBrid.
Slovenian: Razpon skupnega nanesenega odmerka je bil 5 do 30 g koncentrata proteolitičnih encimov, obogatenih z bromelainom iz zdravila NexoBrid.
English: Before prescribing NexoBrid
Slovenian: Pred predpisovanjem zdravila NexoBrid
English: Eyes should be carefully protected during treatment of facial burns using adhesive barrier petroleum ointment.
Slovenian: Med zdravljenjem obraznih opeklin je treba oči skrbno zaščititi z adhezivno pregradno vazelinsko mastjo.
English: • The wound must be wiped thoroughly first with a large sterile dry gauze or napkin, followed by a sterile gauze or napkin that has been soaked with sterile isotonic sodium chloride 9 mg/ml (0.9%) solution.
Slovenian: • Rano morate temeljito obrisati z veliko sterilno suho gazo ali brisačo, nato pa s sterilno gazo ali brisačo, namočeno v sterilno izotonično 0,9-odstotno raztopino natrijevega klorida (9 mg/ml).